The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study
NCT ID: NCT05135013
Last Updated: 2021-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-11-16
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Setting. Breast cancer clinic and breast cancer screening unit at clinical oncology department, Ain Shams University hospital
Participants.
All cases who will be screened from the BC clinic and the BC screening unit will be assessed for eligibility according to the following inclusion \& exclusion criteria:
Inclusion criteria
Age \> 18 and \< 70
Exclusion criteria
* Diagnosed with other concurrent malignancies.
* A prior history of another cancer.
Eligible candidates will be stratified as cases or matched controls as follows:
1. Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Ethical consideration. The protocol will be approved by the ethical committee of NGU and the Clinical Oncology department ASU. The study will be registered at clinicaltrials.gov
Methods.
Data collection for both groups will be done through reviewing of the participants' medical records retrospectively Data collection will include the following data:
* Demographic data: name, age, sex, residence
* Anthropometric data: height, weight, waist \& hip circumference \& waist to hip ratio and BMI calculation
* Female \& menopausal status, age at menarche
* Medical history \& comorbidity (CVS, DM 1 or 2, HTN)
* Family history of other cancers, diabetes
* Occupational history
* Social history: smoking, recreational drug use, marital status, nulliparity/multi-parity and lactation
* Dietary habits and diet composition
* Lifestyle habits and degree of regular activity (sedentary, active, etc.)
* History of hormonal use as follows:
1. Reason for hormonal use: contraception, fertility promotion, PCOS
2. Duration of hormonal use
3. Type of hormonal drug used: dose, hormone type, route of administration
* Breast cancer classification:
1. \- Type of pathology - 2- Molecular classification (ER, PR, Her2 receptors status) 3- Staging of BC.
Statistical analysis The frequency distribution of the parameters will be assessed. Parametric data will be presented as mean \& standard deviation, while non parametric data will be presented as median \& IQR. All data will be analyzed using the appropriate statistical test. Proportions will be presented using number \& proportion and will be assessed by the Chi square.
Multiple logistic regression analysis will be used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for the various studied factors in relation to breast cancer occurrence \& subtypes.
Moreover, the effect of the combined significant factors to the risk of breast cancer development will be evaluated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
History of hormonal use as follows:
1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)
2. Duration of hormonal use
3. Type of hormonal drug used: dose, hormone type, route of administration
Matched Controls
2\. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
History of hormonal use as follows:
1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)
2. Duration of hormonal use
3. Type of hormonal drug used: dose, hormone type, route of administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
History of hormonal use as follows:
1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)
2. Duration of hormonal use
3. Type of hormonal drug used: dose, hormone type, route of administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* A prior history of another cancer.
18 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
NewGiza University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nermeen Ashoush
Lecturer in Clinical Pharmacy Practice Department
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NewGiza University Protocol 1
Identifier Type: -
Identifier Source: org_study_id